Clinical efficacy and safety of secukinumab in the treatment of seven cases of erythrodermic psoriasis
- VernacularTitle:司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察
- Author:
Tingting ZHANG
1
;
Fengyi ZHU
;
Mei YANG
;
Ping ZHANG
;
Ping XIA
;
Xiaoyong ZHOU
Author Information
- Keywords: Psoriasis; Treatment outcome; Biological agents; Erythrodermic; Secukinumab
- From: Chinese Journal of Dermatology 2022;55(10):892-894
- CountryChina
- Language:Chinese
- Abstract: Objective:To evaluate clinical efficacy and safety of secukinumab in the treatment of erythrodermic psoriasis.Methods:From July 2019 to August 2021, 7 patients with erythrodermic psoriasis, who received subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every-4-week dosing in Wuhan Hospital of Integrated Traditional Chinese and Western Medicine, were collected. At weeks 0, 4, 8 and 12, the psoriasis area and severity index (PASI) was recorded, and adverse drug reactions were observed.Results:All 7 patients were treated for at least 12 weeks. After 4-week treatment, 4 patients achieved PASI50; after 12-week treatment, 5 achieved PASI75, and 2 achieved PASI90. No serious adverse drug reactions occurred. One patient developed fever during the treatment, but the body temperature returned to normal after management; another 1 developed cough and expectoration, and the symptoms were relieved after oral administration of a Chinese herbal preparation named pharyngitis mixture.Conclusion:Secukinumab is effective in the treatment of erythrodermic psoriasis, with fewer adverse reactions, which provides a new option for the treatment of erythrodermic psoriasis.
